| Disease | Advanced cancer, prostate cancer |
| Stage of Disease/Treatment | Metastatic/advanced |
| Prior Therapy | No designated number of regimens |
| Type of Study | Phase II, randomized |
| Primary Endpoint | Safety, bone metabolism markers |
| Secondary Endpoint | Overall survival, PSA–progression‐free survival, radiographic progression‐free survival |
| Additional Details of Endpoints or Study Design | Post hoc analysis values of PSA‐PFS2 (time from start of protocol therapy to PSA progression on subsequent therapy) and TTNT |
| Investigator's Analysis | Active and should be pursued further |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.